ERBB2 and breast carcinoma: However, in‐depth study of these patients’ CTCs can shed light on CTC genomic actionable biomarkers, intrapatient heterogeneity, and clonal mechanisms of progression in metastatic ER POS, HER2 NEG breast cancer.